Erratum to: Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach [Tumor Biol., (2014), 35, 5029-5036, 10.1007/s13277-014-1664-z];Differential expression of Pim-3, c-Myc, and p-p27 proteins in adenocarcinomas of the gastric cardia and distal stomach

Tumor Biology

Volumn 35, Issue 5, 2014, Pages 5029-5036

  Li, Yuehong ^a   Lou, Lei ^a   Wang, Yuan ^a   Cui, Jinfeng ^a   Yan, Xia ^a   Xue, Liying ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

c Myc; Cardiac adenocarcinoma; Distal adenocarcinoma; Gastric cancer; p p27; Pim 3

Indexed keywords

MYC PROTEIN; PIM 3 PROTEIN; PROTEIN P27; TUMOR PROTEIN; UNCLASSIFIED DRUG; CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MYC PROTEIN, HUMAN; ONCOPROTEIN; PIM3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CARDIA; CONTROLLED STUDY; DISTAL STOMACH ADENOCARCINOMA; FEMALE; GASTRIC CARDIA ADENOCARCINOMA; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; TUMOR DIFFERENTIATION; ADENOCARCINOMA; AGED; CHEMISTRY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR;

ADENOCARCINOMA; ADULT; AGED; CARDIA; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; STOMACH NEOPLASMS;

EID: 84902967628     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2291-4     Document Type: Erratum

References (48)

1. Varadhachary G, Ajani JA. Gastric cancer. Clin Adv Hematol Oncol. 2005;3:118-24. (Pubitemid 41403325)
2. Pera M. Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. Recent Results Cancer Res. 2000;155:1-14.
3. Richards DA, Boehm KA, Anthony SP. Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs. 2007;16:1059-68. (Pubitemid 47074160)
4. Zhao C, Zhang X, Xue L, Xing L, Wang J, Li X. Analysis of the changing trends of frequency and localization of gastric cancers arising fromdifferent sites of the stomach in population of the high incidence area of esophageal and gastriccancers in Hebei Province. Zhonghua Zhong Liu Za Zhi. 2008;30:817-20.
5. Ichikura T, Ogawa T, Kawabata T, Chochi K, Sugasawa H, Mochizuki H. Is adenocarcinoma of the gastric cardia a distinct entity independent of subcardial carcinoma? World J Surg. 2003;27:334-8. (Pubitemid 36920147)
6. MacDonald WC, MacDonald JB. Adenocarcinoma of the esophagus and/or gastric cardia. Cancer. 1987;60:1094-8. (Pubitemid 17157226)
7. Gray JR, Coldman AJ,MacDonald WC. Cigarette and alcohol use in patients with adenocarcinoma of the gastric cardia or lower esophagus. Cancer. 1992;69:2227-31.
8. Yao D, Wang Y, Xue L, Wang H, Zhang J, Zhang X. Different expression pattern and significance of p14ARF-Mdm2-p53 pathway and Bmi-1 exist between gastric cardia and distal gastric adenocarcinoma. Hum Pathol. 2013;44:844-51.
9. Xue L, Zhang X, Li Y, Yang H, Li X, Mi J, et al. Differences of immunophenotypic markers and signaling molecules between adenocarcinomas of gastric cardia and distal stomach. Hum Pathol. 2011;42:594-601.
10. Mukaida N, Wang YY, Li YY. Roles of Pim-3, a novel survival kinase, in tumorigenesis. Cancer Sci. 2011;102:1437-42.
11. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol. 2008;134:481-8. (Pubitemid 351322384)
12. Forshell LP, Li Y, Forshell TZ, Rudelius M, Nilsson L, Keller U, et al. The direct Myc target Pim3 cooperates with other pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget. 2011;2:448-60.
13. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68:5076-85.
14. Zhang L, Hou Y, Ashktorab H, Gao L, Xu Y, Wu K, et al. The impact of C-MYC gene expression on gastric cancer cell.Mol Cell Biochem. 2010;344:125-35.
15. Lee KH, Lee HE, Cho SJ, Cho YJ, Lee HS, Kim JH, et al. Immunohistochemical analysis of cell cycle-related molecules in gastric carcinoma: prognostic significance, correlation with clinicopathological parameters, proliferation and apoptosis. Pathobiology. 2008;75:364-72.
16. Siewert JR, Holscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification. Chirurg. 1987;58:25-32. (Pubitemid 17007476)
17. Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol. 2005;90:139-46. discussion 146.
18. Flejou JF. WHO classification of digestive tumors: the fourth edition. Ann Pathol. 2011;31:S27-31.
19. Kwon SJ. Evaluation of the 7th UICC TNMstaging system of gastric cancer. J Gastric Cancer. 2011;11:78-85.
20. Zhu S, Sun P, Zhang Y, Yan L, Luo B. Expression of c-myc and PCNA in epstein-barr virus-associated gastric carcinoma. Exp Ther Med. 2013;5:1030-4.
21. He SM, Zhao ZW, Wang Y, Zhao JP, Wang L, Hou F, et al. Potential role of Jun activation domain-binding protein 1 and phosphorylated p27 expression in prognosis of glioma. Brain Tumor Pathol. 2012;29:3-9.
22. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood. 2005;105:4477-83. (Pubitemid 40720797)
23. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C, Mukaida N. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res. 2006;66:6741-7. (Pubitemid 44085632)
24. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, et al. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent bad-mediated apoptosis. Cancer Sci. 2007;98:321-8. (Pubitemid 46195601)
25. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. Pim serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95:1004-15.
26. Wu Y, Wang YY, Nakamoto Y, Li YY, Baba T, Kaneko S, et al. Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver. Oncogene. 2010;29:2228-37.
27. ZF H, Y H, Q Z, J J: Significance of Pim-3 expression in gastric carcinoma. Shijie Huaren Xiaohua Zazhi 2008;16:3515-18.
28. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;27:4809-19.
29. Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A. 2011;108:528-33.
30. Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res. 2007;5:909-22. (Pubitemid 47416668)
31. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, et al. The cell cycle inhibitor p27 is an independent prognosticmarker in small (t1a, b) invasive breast carcinomas. Cancer Res. 1997;57:1259-63. (Pubitemid 27152548)
32. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227-30. (Pubitemid 27064710)
33. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997;3:231-4. (Pubitemid 27064711)
34. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381-5. (Pubitemid 27355479)
35. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 1998;58:542-8. (Pubitemid 28087420)
36. Ohtani M, Isozaki H, Fujii K, Nomura E, Niki M, Mabuchi H, et al. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma. Cancer. 1999;85:1711-8. (Pubitemid 29169671)
37. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41-7. (Pubitemid 36269179)
38. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 1997;15:1133-41. (Pubitemid 27429616)
39. van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989;56:673-82. (Pubitemid 19065532)
40. Mikkers H, Allen J, Knipscheer P, Romeijn L, Hart A, Vink E, et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32:153-9. (Pubitemid 34977211)
41. Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 2007;26:2562-74. (Pubitemid 46788317)
42. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20:1688-702. (Pubitemid 32368016)
43. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996;15:6595-604. (Pubitemid 26413792)
44. Muller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, et al. Cdk2-dependent phosphorylation of p27 facilitates its myc-induced release from cyclin e/cdk2 complexes. Oncogene. 1997;15:2561-76. (Pubitemid 27507248)
45. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J. 1999;18:5310-20. (Pubitemid 29465581)
46. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321-33. (Pubitemid 29465582)
47. Alves MK, Lima VP, Andre AR, Ferreira MV, Barros MA, Rabenhorst SH. p27KIP1 expression in gastric cancer: differential pathways in the histological subtypes associated with Helicobacter pylori infection. Scand J Gastroenterol. 2010;45:409-20.
48. Gulmann C, Hegarty H, Grace A, Leader M, Patchett S, Kay E. Differences in proximal (cardia) versus distal (antral) gastric carcinogenesis via the retinoblastoma pathway. World J Gastroenterol. 2004;10:17-21. (Pubitemid 38071970)